Pharma Grade Sodium Selenite (USP/BP/EP)

Injectable Trace Element Admixtures in Parenteral Nutrition Compounding

Pharma-grade sodium selenite is metered into hospital pharmacy sterile compounding workflows as the selenium source for adult and paediatric total parenteral nutrition. The active species is selenite, Se(IV), which is converted in vivo to selenocysteine for selenoprotein P and glutathione peroxidase synthesis. Selenium dosing in parenteral nutrition follows ASPEN clinical recommendations of 60–100 µg/day for adults and 2–3 µg/kg/day for paediatric patients, with compounding accuracy controlled by automated gravimetric compounders having a minimum weigh tolerance of 0.1 g. The API must meet the USP Sodium Selenite monograph assay range of 98.0–101.0% on the dried basis, and elemental impurity limits are governed by ICH Q3D with a parenteral selenium permitted daily exposure of 80 µg/day. Aluminium contribution is separately controlled because FDA 21 CFR 201.323 requires labelling when aluminium exceeds 25 µg/L in large-volume parenterals.

The principal process conflict is the redox incompatibility of selenite in admixtures containing ascorbic acid. In aqueous parenteral nutrition at pH above 5.5, ascorbic acid reduces Se(IV) to elemental selenium, producing a red colloidal precipitate within 4–8 h at ambient temperature. Trace element injections are therefore formulated as acidic solutions, typically pH 1.8–2.5, to suppress this reduction. During total nutrient admixture compounding, the acidic trace element injection is added to the amino acid-dextrose phase before lipid emulsion addition, because direct contact with the lipid phase can destabilise the emulsion. The finished bag is visually inspected per USP <790>, and subvisible particulate integrity is confirmed by light obscuration according to USP <788>. Terminal heat sterilisation of the mixed admixture is not performed; all components are sterile-filtered through 0.2 µm PVDF membranes in ISO Class 5 laminar airflow workbenches located in ISO Class 7 buffer rooms. Selenium-containing trace element solutions and multivitamin infusions are administered through separate lines to minimise contact time in the infusion set.

Prior to dry blending of pharma-grade sodium selenite into oral tablets or capsules, the formulator corrects for the water of crystallisation if the pentahydrate form is purchased; the pentahydrate contributes 34.2% water by mass, shifting the assay calculation unless the compendial monograph specifies the anhydrous basis. Low-dose selenium tablets commonly contain 50–200 µg elemental selenium per unit, requiring geometric dilution or a spray-dried premix because direct addition of the selenium salt at 0.1–0.5% of tablet mass produces unacceptable content uniformity drift. A validated trituration sequence with dibasic calcium phosphate anhydrous and microcrystalline cellulose is processed in a V-blender with an intensifier bar; a representative validation run uses 25 RPM for 15 min, followed by lubrication with magnesium stearate at 0.5–1.0% w/w. Content uniformity is verified per USP <905>, and dissolution is assessed using USP <711> Apparatus II at 50 RPM in 900 mL deaerated water at 37.0 °C. Selenium content in the finished product is measured by ICP-MS against NIST SRM 3149 selenium standard after microwave-assisted acid digestion. Because anhydrous sodium selenite is hygroscopic, granulation and compression suites are maintained below 60% RH, and finished product is packaged in HDPE bottles with induction seals and silica gel desiccant canisters. Storage is maintained below 25 °C with protection from light. Reducing excipients such as ascorbic acid are excluded from the same tablet matrix because accelerated stability data at 40 °C/75% RH show selenite reduction to elemental selenium, visible as pink specks.

Why Does Sodium Selenite Concentration in Mammalian Cell Culture Media Require ppb-Level Control?

In chemically defined and serum-free mammalian cell culture media, sodium selenite functions as the sole selenium source for selenoprotein biosynthesis in Chinese hamster ovary cells, hybridomas, and human embryonic kidney 293 platforms. Basal formulations derived from DMEM/F12 generally contain sodium selenite at 5 µg/L, equivalent to approximately 29 nM selenium. This concentration sits within the growth-supporting window of 5–50 nM, while toxicity is commonly reported above 200 nM due to redox cycling and increased intracellular reactive oxygen species. Fed-batch media preparation therefore uses dedicated trace element stock solutions pumped into the bioreactor via peristaltic feeds separate from cysteine-rich amino acid feeds. This separation avoids the direct interaction between selenite and thiol-containing feed components, which can convert Se(IV) into non-bioavailable selenium adducts or elemental selenium at neutral pH. In production-scale 2,000 L stirred-tank bioreactors, selenium residual is monitored daily by quadrupole ICP-MS with collision cell technology using NIST SRM 3149 calibration. The lower analytical limit of quantification is established at 0.1 µg/L in culture supernatant. Downstream clarification by depth filtration and 0.2 µm filtration does not remove soluble selenite, but sterile filtration of the trace element feed through polyethersulfone membranes requires mass balance confirmation because low-level selenium adsorption can occur at concentrations below 10 µg/L. Media hold time at 2–8 °C is restricted to 72 h after trace element addition unless on-line selenium speciation indicates no selenite loss.

Injectable selenium deficiency correction in ruminants and other food-producing species uses pharma-grade sodium selenite in aqueous injection formulations, often combined with tocopherol acetate as vitamin E. The formulation is prepared as a sterile solution, adjusted to pH 2.0–3.0 with hydrochloric acid to maintain Se(IV) solubility, and filled into amber glass vials under nitrogen overlay. Terminal sterilisation by autoclave at 121.1 °C for 15 min is applied only after headspace oxygen is displaced with nitrogen. Sterility is verified by membrane filtration per USP <71>, bacterial endotoxin content is controlled per USP <85>, and particulate matter is measured by USP <788>. The finished injection is administered by subcutaneous or intramuscular route at selenium doses based on species body weight, with regional maximum residue limits for selenium in meat and milk governing withdrawal periods. Sodium selenite and selenious acid are not freely interchangeable in species-specific formulations because the salt form influences osmolality and local injection tolerance. Process water for injection is monitored for dissolved oxygen below 0.5 mg/L because dissolved oxygen accelerates oxidation of trace reducing agents present in the formulation matrix.

When Sodium Selenite Is Aseptically Dosed into Ready-to-Hang Enteral Medical Nutrition Formulations

In liquid ready-to-hang medical nutrition formulations for enteral administration, pharma-grade sodium selenite is added as a trace element source before retort or ultra-high-temperature processing. The formulation pH is typically between 6.2 and 6.8, which lies above the selenite stability threshold in the presence of ascorbic acid and reducing sugars; therefore, the selenium salt is metered into the cooled intermediate after thermal processing through an aseptic addition step. This late addition step uses a 0.2 µm sterilising-grade PVDF filter and a stainless steel dosing vessel blanketed with nitrogen. The final selenium level is targeted to deliver 50–70 µg selenium per 250 mL serving, consistent with the European Food Safety Authority adult adequate intake of 70 µg/day. Selenium content is quantified by ICP-MS after closed-vessel microwave digestion using NIST SRM 3149 calibration. Stability data from retort-processed batches show selenium recovery within 95–105% of label claim for 12 months at 25 °C/60% RH when stored in multilayer plastic bags with oxygen barrier properties. Substitution with selenium yeast is not permitted where the product is intended for medical nutrition protocols requiring a defined inorganic selenium species. The manufacturing line is cleaned with 1% citric acid solution after selenium-containing batches to avoid cross-contact with reducing intermediates.